The conference entitled “Recent Advances in Understanding and Treating Myeloid Neoplasms”, that will be held at the University of Florence from 8 to 10 September 2016, holds the promise to be a very successful event for the growing community of researchers and clinicians involved in the field, and we do hope it will attract as well as colleagues from related basic and clinical disciplines. This convention happens just 10 years after the discovery of the first recurrent mutation in JAK2 in patients with chronic myeloproliferative neoplasms and 5 years after the approval of the first JAK2 inhibitor for the treatment of myelofibrosis. Remarkably, it took as long as 50 years of efforts to shed light on the molecular basis of these disorders after the original theorization by W. Dameshek in 1951. Many of the scientists and clinicians that have been instrumental in this process will intervene to the conference presenting the latest news and discussing the next steps. Indeed, although we now know a lot of these disorders and are able to more effectively managing them and improving the quality of life of the patients, much remains to be understood and the ultimate goal of a cure still appears sadly far. The knowledge accumulated in the last years in chronic myeloid neoplasms is an excellent example of how basic researchers, research scientists and clinicians can successfully collaborate and integrate their own skills to generate new approaches for understanding the molecular basis of diseases, improving diagnosis, refining prognostication methods and developing a framework for innovative therapies. On behalf of the scientific committee, the speakers and chairs, I look forward to welcome you in Florence for a very productive conference.
Please fill out the Form in order to proceed with your registration
With the patronage of
Associazione Italiana per la Ricerca sul Cancro (AIRC)
SIE (Società Italiana di Ematologia)
Società Italiana di Ematologia Sperimentale (SIES)
Gruppo Italiano Trapianti di Midollo Osseo (GITMO)